The following foundations and societies may have information about ineffective erythropoiesis and the various disease states affected by chronic anaemia. This list of independent organisations is provided as an additional resource for obtaining information. Inclusion on this list does not indicate endorsement by Celgene Corporation of an organisation or its communications.
As of 25th June 2020, luspatercept is indicated for the treatment of:
Please visit www.Reblozyl.be for further information (restricted access to healthcare professionals)
The Thalassaemia International Federation (TIF)